Cargando…
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder, typically characterized by anovulation, infertility, obesity, insulin resistance, and polycystic ovaries. Lifestyle or diet, environmental pollutants, genetics, gut dysbiosis, neuroendocrine alterations, and obesity are...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964744/ https://www.ncbi.nlm.nih.gov/pubmed/36835989 http://dx.doi.org/10.3390/jcm12041454 |
_version_ | 1784896584021966848 |
---|---|
author | Singh, Samradhi Pal, Namrata Shubham, Swasti Sarma, Devojit Kumar Verma, Vinod Marotta, Francesco Kumar, Manoj |
author_facet | Singh, Samradhi Pal, Namrata Shubham, Swasti Sarma, Devojit Kumar Verma, Vinod Marotta, Francesco Kumar, Manoj |
author_sort | Singh, Samradhi |
collection | PubMed |
description | Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder, typically characterized by anovulation, infertility, obesity, insulin resistance, and polycystic ovaries. Lifestyle or diet, environmental pollutants, genetics, gut dysbiosis, neuroendocrine alterations, and obesity are among the risk factors that predispose females to PCOS. These factors might contribute to upsurging metabolic syndrome by causing hyperinsulinemia, oxidative stress, hyperandrogenism, impaired folliculogenesis, and irregular menstrual cycles. Dysbiosis of gut microbiota may play a pathogenic role in the development of PCOS. The restoration of gut microbiota by probiotics, prebiotics, or a fecal microbiota transplant (FMT) might serve as an innovative, efficient, and noninvasive way to prevent and mitigate PCOS. This review deliberates on the variety of risk factors potentially involved in the etiology, prevalence, and modulation of PCOS, in addition to plausible therapeutic interventions, including miRNA therapy and the eubiosis of gut microbiota, that may help treat and manage PCOS. |
format | Online Article Text |
id | pubmed-9964744 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99647442023-02-26 Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics Singh, Samradhi Pal, Namrata Shubham, Swasti Sarma, Devojit Kumar Verma, Vinod Marotta, Francesco Kumar, Manoj J Clin Med Review Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder, typically characterized by anovulation, infertility, obesity, insulin resistance, and polycystic ovaries. Lifestyle or diet, environmental pollutants, genetics, gut dysbiosis, neuroendocrine alterations, and obesity are among the risk factors that predispose females to PCOS. These factors might contribute to upsurging metabolic syndrome by causing hyperinsulinemia, oxidative stress, hyperandrogenism, impaired folliculogenesis, and irregular menstrual cycles. Dysbiosis of gut microbiota may play a pathogenic role in the development of PCOS. The restoration of gut microbiota by probiotics, prebiotics, or a fecal microbiota transplant (FMT) might serve as an innovative, efficient, and noninvasive way to prevent and mitigate PCOS. This review deliberates on the variety of risk factors potentially involved in the etiology, prevalence, and modulation of PCOS, in addition to plausible therapeutic interventions, including miRNA therapy and the eubiosis of gut microbiota, that may help treat and manage PCOS. MDPI 2023-02-11 /pmc/articles/PMC9964744/ /pubmed/36835989 http://dx.doi.org/10.3390/jcm12041454 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Singh, Samradhi Pal, Namrata Shubham, Swasti Sarma, Devojit Kumar Verma, Vinod Marotta, Francesco Kumar, Manoj Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics |
title | Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics |
title_full | Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics |
title_fullStr | Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics |
title_full_unstemmed | Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics |
title_short | Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics |
title_sort | polycystic ovary syndrome: etiology, current management, and future therapeutics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964744/ https://www.ncbi.nlm.nih.gov/pubmed/36835989 http://dx.doi.org/10.3390/jcm12041454 |
work_keys_str_mv | AT singhsamradhi polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics AT palnamrata polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics AT shubhamswasti polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics AT sarmadevojitkumar polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics AT vermavinod polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics AT marottafrancesco polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics AT kumarmanoj polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics |